STAT5A is frequently implicated in oncogenic processes, particularly in breast and hematologic cancers [5,19], whereas STAT5B more consistently associates with favorable survival outcomes in epithelial tumors and B-cell lymphomas. This evidence concerns the gene STAT5B and hematopoietic and lymphoid cell neoplasm.